Panel hears bill to require validated non‑animal test methods in drug development
Supporters told the Consumer Protection and Business Committee HB 2542 would require use of validated non‑animal test methods in drug development when available; industry witnesses urged care to avoid hindering research where alternatives are not yet adequate. The committee heard broad public support and staff briefing on federal FDA developments.
The full story
The Consumer Protection and Business Committee heard testimony Jan. 27 on House Bill 2542, which would prohibit use of animal test methods in drug development when a validated, non‑animal alternative that provides information of equivalent or better scientific quality is available.
Sign up to keep reading.
Your free newsletter brings you what your city council, county, and school board discussed and decided.
Keep reading for free
Create a free account to finish this story and see the video, transcript and key details.
Continue with GoogleContinue with emailAlready have an account? Log in